Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
165.72
8.3 (5.27%)
Market Cap: 20.96 Bil
Enterprise Value: 19.89 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 67/100 - Q1 2024 Alnylam Pharmaceuticals Inc Earnings Call TranscriptMay 02, 2024$150.31 (+0.23%)Earnings
- Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call TranscriptFeb 15, 2024$147.43 (-10.19%)Earnings
- Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Alnylam Pharmaceuticals Inc R&D Day TranscriptDec 13, 2023
- Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2023
- Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference TranscriptNov 14, 2023
- Alnylam Pharmaceuticals Inc at Jefferies London Healthcare Conference TranscriptNov 14, 2023
- Q3 2023 Alnylam Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2023$161.53 (+2.89%)Earnings
- Alnylam Pharmaceuticals Inc To Host Investor Call TranscriptOct 09, 2023
- Alnylam Pharmaceuticals Inc at Canaccord Genuity Growth Conference TranscriptAug 10, 2023
- Q2 2023 Alnylam Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2023$190.1 (+1.65%)Earnings
- Alnylam Pharmaceuticals Inc to Discuss Collaboration with Roche TranscriptJul 24, 2023
- Alnylam Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Alnylam Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Alnylam Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2023$205.39 (+2.95%)Earnings
- Alnylam Pharmaceuticals Inc ALN-APP Call TranscriptApr 26, 2023
- Alnylam Pharmaceuticals Inc at Ginkgo Bioworks Ferment Conference TranscriptApr 19, 2023
- Alnylam Pharmaceuticals Inc at Stifel CNS Days (Virtual) TranscriptMar 29, 2023
- Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2023
- Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- Alnylam Pharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- Q4 2022 Alnylam Pharmaceuticals Inc Earnings Call TranscriptFeb 23, 2023$196.24 (-2.42%)Earnings
- Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Alnylam Pharmaceuticals Inc R&D Day TranscriptDec 15, 2022
- Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- Alnylam Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference TranscriptNov 16, 2022
- Alnylam Pharmaceuticals Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: CNS Delivery and ALN-APP, in Development for the Treatment of Alzheimer's Disease and Cerebral Amyloid Angiopathy TranscriptNov 01, 2022
- Q3 2022 Alnylam Pharmaceuticals Inc Earnings Call TranscriptOct 27, 2022$194 (-3.49%)Earnings
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Alnylam Engine for Sustainable Innovation: Leadership in RNAi Platform and Human Genetics TranscriptOct 21, 2022
- Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Results at HFSA Scientific Meeting TranscriptOct 01, 2022
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Cemdisiran, in Development for the Treatment of IgA Nephropathy (IgAN) and Other Complement-Mediated Diseases TranscriptSep 27, 2022
- Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Results - Conference Call TranscriptSep 08, 2022
- Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Topline Results TranscriptAug 03, 2022
- Q2 2022 Alnylam Pharmaceuticals Inc Earnings Call TranscriptJul 28, 2022$143.52 (+1.09%)Earnings
- Alnylam Pharmaceuticals Inc to Discuss FDA Approval of AMVUTTRA (Vutrisiran) TranscriptJun 14, 2022
- Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 13, 2022
- Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 25, 2022
- Alnylam Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptMay 24, 2022
- Alnylam Pharmaceuticals Inc at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 Alnylam Pharmaceuticals Inc Earnings Call TranscriptApr 28, 2022$143.16 (-7.59%)Earnings
- Alnylam Pharmaceuticals Inc at Stifel CNS Days (Virtual) TranscriptMar 28, 2022
- Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2022
- Alnylam Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) TranscriptMar 08, 2022
- Alnylam Pharmaceuticals Inc at SVB Leerink Global Healthcare (Virtual) TranscriptFeb 17, 2022
- Q4 2021 Alnylam Pharmaceuticals Inc Earnings Call TranscriptFeb 10, 2022$150.86 (-0.36%)Earnings
- Alnylam Pharmaceuticals Inc to Present HELIOS-A 18-Month Results - Conference Call TranscriptJan 21, 2022
- Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference (Virtual) TranscriptDec 02, 2021
- Alnylam Pharmaceuticals Inc at Evercore ISI HealthCONx Virtual Conference TranscriptNov 30, 2021
- Alnylam Pharmaceuticals Inc Virtual R&D Day TranscriptNov 19, 2021
- Q3 2021 Alnylam Pharmaceuticals Inc Earnings Call TranscriptOct 28, 2021$162.14 (-15.18%)Earnings
- Alnylam Pharmaceuticals Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: CNS & Extrahepatic RNAi Pipeline Programs TranscriptOct 01, 2021
- Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 28, 2021
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Liver-Directed RNAi Pipeline Programs TranscriptSep 20, 2021
- Alnylam Pharmaceuticals Inc at Bank of America Global Healthcare Conference (Virtual) TranscriptSep 16, 2021
- Alnylam Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 13, 2021
- Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, for the Treatment of Primary Hyperoxaluria Type 1 TranscriptAug 19, 2021
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Givosiran, for the Treatment of Acute Hepatic Porphyria TranscriptAug 04, 2021
- Q2 2021 Alnylam Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2021$178.81 (+0.48%)Earnings
- Alnylam Pharmaceuticals Inc "RNAi Roundtable" Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of ATTR Amyloidosis TranscriptJul 16, 2021
- Alnylam Pharmaceuticals Inc "RNAi Roundtable” Webcast Series: ALN-AGT, in Development for the Treatment of Hypertension TranscriptJun 30, 2021
- Alnylam Pharmaceuticals Inc at Nasdaq Investor Conference (Virtual) TranscriptJun 15, 2021
- Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Alnylam Pharmaceuticals Inc at Sanford C Bernstein Strategic Decisions Conference (Virtual) TranscriptJun 03, 2021
- Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Alnylam Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Alnylam Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 18, 2021
- Alnylam Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 11, 2021
- Q1 2021 Alnylam Pharmaceuticals Inc Earnings Call TranscriptApr 29, 2021$139.69 (-2.68%)Earnings
- Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call TranscriptApr 19, 2021
- Alnylam Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 13, 2021
- Alnylam Pharmaceuticals Inc at Stifel CNS Day TranscriptApr 01, 2021
- Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Alnylam Pharmaceuticals Inc at H C Wainwright Global Life Sciences Conference (Virtual) TranscriptMar 09, 2021
- Alnylam Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 01, 2021
- Alnylam Pharmaceuticals Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- Q4 2020 Alnylam Pharmaceuticals Inc Earnings Call TranscriptFeb 11, 2021$165.38 (+0.74%)Earnings
- Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Alnylam Pharmaceuticals Inc to Discuss Topline HELIOS-A Phase 3 Results of Vutrisiran - Conference Call TranscriptJan 07, 2021
- Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 2) TranscriptDec 16, 2020
- Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 1) TranscriptDec 15, 2020
- Alnylam Pharmaceuticals Inc at Nasdaq Virtual Investor Conference TranscriptDec 04, 2020
- Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call TranscriptNov 24, 2020
- Alnylam Pharmaceuticals Inc at Stifel Virtual Healthcare Conference TranscriptNov 16, 2020
- Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 09, 2020
- Q3 2020 Alnylam Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$137.86 (-1.17%)Earnings
- Alnylam Pharmaceuticals Inc at H C Wainwright Hepatitis B Virus (HBV) Mini-Conference (Virtual) TranscriptOct 20, 2020
- Alnylam Pharmaceuticals Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2020
- Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Alnylam Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2020
- BridgeBio Pharma Inc at Citi BioPharma Conference (Virtual)- Panel: TTR Amyloidosis TranscriptSep 09, 2020
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis TranscriptSep 03, 2020
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I TranscriptAug 10, 2020
- Q2 2020 Alnylam Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020$144.12 (-4.20%)Earnings
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Early Stage RNAi Therapeutics Pipeline TranscriptJul 17, 2020
- Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) TranscriptJun 24, 2020
- Alnylam Pharmaceuticals Inc "RNAi Roundtable” Webcast Series: ALN-AGT, in Development for the Treatment of Hypertension TranscriptJun 23, 2020
- Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Alnylam Pharmaceuticals Inc to Discuss Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress TranscriptJun 07, 2020
- Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2020
- Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Alnylam Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 06, 2020
- Q1 2020 Alnylam Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2020$145.27 (+2.86%)Earnings
- Alnylam Pharmaceuticals Inc at Needham Healthcare Conference TranscriptApr 14, 2020
- Alnylam Pharmaceuticals Inc Conference Call to Discuss Strategic Financing Collaboration with Blackstone TranscriptApr 13, 2020
- Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 10, 2020
- Alnylam Pharmaceuticals Inc at Cowen HealthCare Conference TranscriptMar 03, 2020
- Alnylam Pharmaceuticals Inc at Leerink Global Healthcare Conference TranscriptFeb 27, 2020
- Q4 2019 Alnylam Pharmaceuticals Inc Earnings Call TranscriptFeb 06, 2020$121.96 (+0.30%)Earnings
- Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Alnylam Pharmaceuticals Inc to Discuss Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran Conference Call TranscriptDec 17, 2019
- Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference TranscriptDec 05, 2019
- Alnylam Pharmaceuticals Inc at Evercore HealthCONx Conference TranscriptDec 04, 2019
- Alnylam Pharmaceuticals Inc R&D Day 2019 TranscriptNov 22, 2019
- Alnylam Pharmaceuticals Inc Conference Call to Discuss FDA Approval of GIVLAARI (Givosiran) TranscriptNov 20, 2019
- Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference TranscriptNov 19, 2019
- Q3 2019 Alnylam Pharmaceuticals Inc Earnings Call TranscriptOct 31, 2019$86.74 (-0.61%)Earnings
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1 TranscriptOct 10, 2019
- Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Givosiran, in Development for the Treatment of Acute Hepatic Porphyria TranscriptOct 07, 2019
- Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptOct 03, 2019
- Alnylam Pharmaceuticals Inc "RNAi Roundtable" Webcast Series: Patisiran & Vutrisiran, for the Treatment of Transthyretin-Mediated Amyloidosis TranscriptSep 16, 2019
- Alnylam Pharmaceuticals Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 Alnylam Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2019$74.38 (+4.16%)Earnings
- Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2019
- Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 16, 2019
- Q1 2019 Alnylam Pharmaceuticals Inc Earnings Call TranscriptMay 01, 2019$83.03 (-7.06%)Earnings
- Alnylam Pharmaceuticals Inc Annual Shareholders Meeting TranscriptApr 25, 2019
- Alnylam Pharmaceuticals Inc to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress Conference Call TranscriptApr 13, 2019
- Alnylam Pharmaceuticals Inc to Discuss Regeneron Collaboration - Call TranscriptApr 08, 2019
- Alnylam Pharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 13, 2019
- Alnylam Pharmaceuticals Inc to Discuss Topline Results from ENVISION Phase 3 Study of Givosiran Conference Call TranscriptMar 06, 2019
- Alnylam Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference TranscriptFeb 27, 2019
- Alnylam Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference TranscriptFeb 11, 2019
- Q4 2018 Alnylam Pharmaceuticals Inc Earnings Call TranscriptFeb 07, 2019$80.8 (-1.17%)Earnings
Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2023 / 12:00PM GMT
Release Date Price:
$189.66
(+2.10%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst
Good morning, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at Barclays. Welcome to Barclays Global Healthcare Conference. Today is the last day, and I hope everyone had a very productive meetings -- all having additional productive meetings. It is my great pleasure to introduce today's first presenting company, Alnylam. With us today, we have Jeff Poulton, Chief Financial Officer; also Eric Green, SVP, Head of Development Profiles. Thank you for coming to our conference.
Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
Thank you. Thanks to Barclays for having us. It's always nice to be in Miami in this time of year.
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst
Yes, certainly better than Boston.
Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
Much better.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)